EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes

Kasper Bonnesen, Uffe Heide-Jørgensen, Diana H Christensen, Christian F Christiansen, Timothy L Lash, Sean Hennessy, Anthony A Matthews, Lars Pedersen, Reimar W Thomsen, Morten Schmidt

JAMA Internal Medicine · 01.03.2025 · 185 (3) · 314

DOI: 10.1001/jamainternmed.2024.7381 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2025. Verfasst von Kasper Bonnesen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance No large randomized clinical trial has directly compared empagliflozin with dapagliflozin, leaving their comparative effectiveness regarding kidney outcomes unknown.

Objective

To compare kidney outcomes between initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who were receiving antihyperglycemic treatment. Design, Setting, and Participants This target trial emulation used nationwide, population-based routinely collected Danish health care data to compare initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who received antihyperglycemic treatment between June 1, 2014, and October 31, 2020. Data were analyzed from October 2023 to August 2024. Persons were followed up until an outcome, emigration, death, 6 years, or December 31, 2021, whichever occurred first. Exposure Initiation of empagliflozin vs dapagliflozin. Main Outcomes and Measures Outcomes included acute kidney injury, incident chronic kidney disease (stages G3 to G5 or stage A2 or A3), and progression of chronic kidney disease (≥40% decrease in estimated glomerular filtration rate from baseline). Risks of kidney outcomes were estimated in intention-to-treat and per-protocol analyses using an Aalen-Johansen estimator that adjusted for 56 potential confounders and considered death as a competing event.

Results

A total of 32 819 individuals who initiated treatment with empagliflozin and 17 464 with dapagliflozin were included (median [IQR] age, 63 [54-71] years; 18 872 female individuals [37.5%]; median [IQR] estimated glomerular filtration rate, 88 [73-104] mL/min/1.73 m 2 ). After weighting, all measured covariates were well balanced between the groups. In intention-to-treat analyses, people who initiated treatment with empagliflozin and dapagliflozin exhibited comparable 6-year risks of acute kidney injury (18.2% vs 18.5%; risk ratio, 0.98; 95% CI, 0.91-1.06), chronic kidney disease stages G3 to G5 (11.8% vs 12.1%; risk ratio, 0.97; 95% CI, 0.89-1.05), chronic kidney disease stage A2 or A3 (14.8% vs 14.3%; risk ratio, 1.04; 95% CI, 0.93-1.15), and progression of chronic kidney disease (5.3% vs 5.7%; risk ratio, 0.94; 95% CI, 0.56-1.58). The primary analyses were supported by corresponding per-protocol analyses. Conclusions and Relevance The results of this cohort study suggest that people with type 2 diabetes who initiated treatment with empagliflozin and dapagliflozin had comparable long-term kidney outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHypoglycemic AgentsDiabetic NephropathiesAcute Kidney InjuryHumansFemaleMaleMiddle AgedAgedGlomerular Filtration RateDenmarkTreatment OutcomeDisease Progression

Substanzen

Benzhydryl CompoundsGlucosidesdapagliflozinempagliflozinSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Zitieren

APA

Bonnesen, K., Heide-Jørgensen, U., Christensen, D. H., Christiansen, C. F., Lash, T. L., Hennessy, S., Matthews, A. A., Pedersen, L., Thomsen, R. W., & Schmidt, M. (2025). Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes. JAMA Internal Medicine, 185(3), 314. https://doi.org/10.1001/jamainternmed.2024.7381

Vancouver

Bonnesen K, Heide-Jørgensen U, Christensen DH, Christiansen CF, Lash TL, Hennessy S, et al. Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes. JAMA Internal Medicine. 2025;185(3):314. doi:10.1001/jamainternmed.2024.7381

BibTeX
@article{Bonnesen2025,
  author = {Bonnesen, Kasper and Heide-Jørgensen, Uffe and Christensen, Diana H and Christiansen, Christian F and Lash, Timothy L and Hennessy, Sean and Matthews, Anthony A and Pedersen, Lars and Thomsen, Reimar W and Schmidt, Morten},
  title = {Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes},
  journal = {JAMA Internal Medicine},
  year = {2025},
  volume = {185},
  number = {3},
  pages = {314},
  doi = {10.1001/jamainternmed.2024.7381}
}
Kostenlos starten →